This year’s top content in the Duchenne muscular dystrophy (DMD) space focused on a novel gene therapy approval, the high cost of care for this genetic disorder, and steps forward in other treatments.
HoneyBadger BFT (HBBFT) consensus, which has been successfully pioneered and deployed by DMD Diamond in its v4 mainnet, ...
Delandistrogene moxeparvovec showed significant long-term stabilization or slowed progression in DMD patients over 3 and 5 years compared to external controls. Clinical trials demonstrated ...
DUBLIN--(BUSINESS WIRE)--The "Duchenne Muscular Dystrophy - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth ...
Wave Life Sciences has met its goal in a Duchenne muscular dystrophy (DMD) study, positioning it to talk to regulators about accelerated approval while continuing to track patients through to the ...
Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy: Opportunity Analysis and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. This report covers ...
Clinical Trials Arena on MSN
Dyne to seek accelerated approval of DMD drug on Phase I/II data
Dyne Therapeutics intends to submit a biologics licence application to the FDA for accelerated approval in Q2 2026.
Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...
Duchenne muscular dystrophy (DMD) occurs as a result of genetic changes on the X chromosome. If someone has a gene change that can cause DMD, their children may inherit that change. DMD is a ...
Early screening for Duchenne muscular dystrophy can help you get early treatments and referrals for your child to help prevent further loss of muscle tissue. Duchenne muscular dystrophy (DMD) is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback